In part 2 of a recent Face Off event hosted by CancerNetwork?, the Memorial Sloan Kettering Cancer Center (MSKCC) "Yankees" were again up against the Dana-Farber Cancer Institute (DFCI) "Red Sox," this time to discuss treatments in multiple myeloma. The MSKCC team was led by Malin Hultcrantz, MD, PhD, and Carlyn Rose Tan, MD, both assistant attending physicians at the cancer center. The DFCI team was led by Omar Nadeem, MD, clinical director of both the Myeloma Immune Effector Cell Therapy Program and the Center for Prevention of Progression and associate director of the Multiple Myeloma Clinical Research Program at DFCI as well as instructor in medicine at Harvard Medical School; and Clifton C. Mo, MD, director of autologous stem cell transplantation for multiple myeloma and associate director of the Multiple Myeloma Clinical Research Program at DFCI as well as assistant professor of medicine at Harvard Medical School. The panelists discussed and debated current preferred treatments for multiple myeloma. Each team was given the chance to defend their choices, and a live audience voted on each presentation to determine a winner.
展开▼
